Immunotherapy for Lymphomas
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://link.springer.com/article/10.1007/BF02986612/fulltext.html
Reference102 articles.
1. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475.
2. Biologic response modifiers: a report.Natl Cancer Inst Monogr. 1983;63:57–59.
3. Fefer A. Interleukin-2: clinical applications—hematologic malignancies. In: Rosenberg SA, ed.Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia: Lippincott Williams &Wilkins; 2000:83–92.
4. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long term complete remissions in non-Hodgkin’s lymphoma patients without eradicating the malignant clone.Blood. 1998;92:1184–1190.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol. 1998;16:2825–2833.
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans;Biology of Blood and Marrow Transplantation;2010-09
2. Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma;Veterinary and Comparative Oncology;2010-08-16
3. Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma;Clinical Cancer Research;2009-10-06
4. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines;Molecular Immunology;2009-01
5. Medical management update: Non-Hodgkin lymphoma;Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology;2009-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3